FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Invention is influenza virus strain A/17/Brisbane/2017/7178 (H3N2) – reassortant produced by crossing epidemic virus A/Brisbane/190/2017 (H3N2) with cold-adapted temperature-sensitive virus A/Leningrad/134/17/57 (H2N2) – an attenuation donor, which is harmless for humans. Strain A/17/Brisbane/2017/7178 (H3N2) actively propagates in developing chick embryos at optimum temperature 32 °C, is characterized by temperature sensitivity and cold tolerance and harmlessness for laboratory animals. Reassortant has inherited genes coding surface antigens of haemagglutinin virus (HA) and neuraminidase (NA), from an epidemic parental virus and the other six genes coding internal and unstructured proteins, from an attenuation donor.
EFFECT: invention makes it possible to prevent influenza incidence in adults and children with the help of live influenza intranasal vaccine of influenza virus A/17/Brisbane/2017/7178 (H3N2) strain.
1 cl, 1 dwg, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| VACCINE STRAIN OF INFLUENZA VIRUS A/17/BRISBANE/2018/3610 (H3N2) FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2019 |
|
RU2734897C1 |
| VACCINE STRAIN OF INFLUENZA VIRUS A/17/SWITZERLAND/2017/51 (H3N2) FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2019 |
|
RU2715674C1 |
| VACCINE STRAIN OF INFLUENZA A/17/KANSAS/2017/631 (H3N2) VIRUS FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2019 |
|
RU2732610C1 |
| VACCINE INFLUENZA VIRUS STRAIN A/17/HONGKONG/2014/8296 (H3N2) FOR PREPARING LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2016 |
|
RU2606019C1 |
| A/17/SINGAPORE/2016/3571 (H3N2) VACCINE INFLUENZA STRAIN FOR PRODUCING LIVE INFLUENZA INTRANAZAL VACCINE FOR ADULTS AND CHILDREN | 2018 |
|
RU2683500C1 |
| REASSORTANT STRAIN OF INFLUENZA VIRUS A/17/HONG KONG/2019/2573 (H3N2) FOR THE PRODUCTION OF LIVE INTRANASAL INFLUENZA VACCINE FOR ADULTS AND CHILDREN | 2022 |
|
RU2783894C1 |
| REASSORTANT VACCINE STRAIN OF INFLUENZA VIRUS A/17/TASMANIA/2020/151 (H3N2) FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND FOR CHILDREN | 2023 |
|
RU2825672C1 |
| REASSORTANT VACCINE STRAIN OF INFLUENZA A/17/MICHIGAN/2020/484 (H3N2) VIRUS FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2023 |
|
RU2825583C1 |
| REASSORTANT VACCINE STRAIN OF INFLUENZA A/17/DARWIN/2021/410 (H3N2) VIRUS FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2023 |
|
RU2825673C1 |
| REASSORTANT STRAIN OF INFLUENZA VIRUS A/17/VICTORIA/2019/276 (H1N1) PDM09 FOR THE PRODUCTION OF LIVE INTRANASAL INFLUENZA VACCINE FOR ADULTS AND CHILDREN | 2022 |
|
RU2783878C1 |
